Background: The botulinum toxin type A (BoNT-A) is used in a wide range of neurological diseases. We aimed to study the overall patients/caregivers’ satisfaction with BoNT-A treatment in different neurological conditions. Methods: Prospective study included patients who had received at least two BoNT-A treatment sessions. They were asked to rate overall treatment satisfaction at the peak of treatment effect on a 1 to 10 scale (1 = not at all satisfied; 10 = fully satisfied). Subjects with a rating of 1to3 were classified as not at all satisfied, those with a rating of 4 to7 as somewhat satisfied, and those with a rating of 8 to10 as very satisfied. Treatment satisfaction questionnaire for medicine (TSQM) was assessed at the end of observational period. Quality of life QOL was assessed before BoNT-A treatment and at the last visit. Results: The study was conducted from first April 2014 to August 2021. 548 patients were identified with mean age 43.66 ± 14.50. Most of participants 389 (71%) were female. At the end of observational period, the mean satisfaction was 7.28 ± 1.78. There was a highly significant difference (P < 0.0001) for treatment satisfaction among different neurological disorders. Total TSQM with BoNT-A was the highest for axillary hyperhidrosis (HH) (90.45 ± 0.62), followed by chronic migraine (72.13 ± 1.59) and the least TSQM was reported in writer’s cramp (40.44 ± 1.57). Overall satisfaction with BoNT-A at the peak of treatment effect among patients with axillary HH (100%), palmar HH (94.4%), neuropathic pain syndromes (85.7%), planter HH (90%), trigeminal neuralgia (80%). While patients with cervical dystonia (86.7%) and musculoskeletal pain (80%) patients were somewhat satisfied. Not at all satisfied rates were recorded among writer’s cramp patients (40%). Total TSQM with BoNT-A was highest for axillary HH 90.45 ± 0.62 and least satisfaction was reported in writer’s cramp 40.44 ± 1.57. QOL significantly improved at the end of observational period (71.93 versus 104.52; P < 0.0001).We reported a positive significant correlation between BoNT-A treatment satisfaction and treatment adherence (r = 0.242, P = 0.001). Conclusion: Satisfaction with BoNT-A therapy for different neurological disorders is overall good. The highest patient satisfaction was observed with primary focal HH, and the least satisfaction was observed in writer’s cramp. BoNT-A therapy improved QOL.
References
[1]
Mor, N., Tang, C. and Blitzer, A. (2015) Temporomandibular Myofacial Pain Treated with Botulinum Toxin Injection. Toxins, 7, 2791-2800. https://doi.org/10.3390/toxins7082791
[2]
Rossetto, O., Pirazzini, M. and Montecucco, C. (2014) Botulinum Neurotoxins: Genetic, Structural and Mechanistic Insights. Nature Reviews Microbiology, 12, 535-549. https://doi.org/10.1038/nrmicro3295
[3]
Waller, R.R., Kennedy, R.H., Henderson, J.W. and Kesty, K.R. (1985) Management of Blepharospasm. Transactions of the American Ophthalmological Society, 83, 367-386.
[4]
Ramachandran, R. and Yaksh, T.L. (2014) Therapeutic Use of Botulinum Toxin in Migraine: Mechanisms of Action. British Journal of Pharmacology, 171, 4177-4192. https://doi.org/10.1111/bph.12763
[5]
Ward, A.B., Molenaers, G., Colosimo, C. and Berardelli, A. (2006) Clinical Value of Botulinum Toxin in Neurological Indications. European Journal of Neurology, 13, 20-26. https://doi.org/10.1111/j.1468-1331.2006.01650.x
[6]
Amorelli, G., Spitz, M., Pereira, L.R. and Vasconcellos, L.F. (2017) Quality of Life and Epidemiological Profile of Patients Undergoing Botulinum Toxin Treatment. Revista Brasileira de Neurologia, 53, 23-26.
[7]
Ihde, S.K. and Konstantinovic, V.S. (2007) The Therapeutic Use of Botulinum Toxin in Cervical and Maxillofacial Conditions: An Evidence-Based Review. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 104, e1-e11. https://doi.org/10.1016/j.tripleo.2007.02.004
[8]
Tinastepe, N., Küçük, B.B. and Oral, K. (2015) Botulinum Toxin for the Treatment of Bruxism. CRANIO®, 33, 292-298. https://doi.org/10.1179/2151090314Y.0000000022
[9]
Esquenazi, A., Albanese, A., Chancellor, M.B., Elovic, E., Segal, K.R., Simpson, D.M., Smith, C.P. and Ward, A.B. (2013) Evidence-Based Review and Assessment of Botulinum Neurotoxin for the Treatment of Adult Spasticity in the Upper Motor Neuron Syndrome. Toxicon, 67, 115-128. https://doi.org/10.1016/j.toxicon.2012.11.025
[10]
Marciniak, C., Munin, M.C., Brashear, A., Rubin, B.S., Patel, A.T., Slawek, J., Hanschmann, A., Hiersemenzel, R. and Elovic, E.P. (2019) Incobotulinumtoxina Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study. Advances in therapy, 36, 187-199. https://doi.org/10.1007/s12325-018-0833-7
[11]
Shikiar, R. and Rentz, A.M. (2004) Satisfaction with Medication: An Overview of Conceptual, Methodologic, and Regulatory Issues. Value in Health, 7, 204-215. https://doi.org/10.1111/j.1524-4733.2004.72252.x
[12]
Barbosa, C.D., Balp, M.M., Kulich, K., Germain, N. and Rofail, D. (2012) A Literature Review to Explore the Link between Treatment Satisfaction and Adherence, Compliance, and Persistence. Patient Prefer Adherence, 6, 39-48. https://doi.org/10.2147/PPA.S24752
[13]
Colosimo, C., Charles, D., Misra, V.P., Maisonobe, P. and Om, S. (2019) INTEREST IN CD2 Study Group. How Satisfied Are Cervical Dystonia Patients after 3 Years of Botulinum Toxin Type A Treatment? Results from a Prospective, Long-Term Observational Study. Journal of Neurology, 266, 3038-3046. https://doi.org/10.1007/s00415-019-09527-2
[14]
Dodick, D.W., Turkel, C.C., DeGryse, R.E., Aurora, S.K., Silberstein, S.D., Lipton, R.B., et al. (2010) OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results from the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain, 50, 921-936. https://doi.org/10.1111/j.1526-4610.2010.01678.x
[15]
Fezza, J, Burns, J., Woodward, J., Truong, D., Hedges, T. and Verma, A. (2016) A Cross-Sectional Structured Survey of Patients Receiving Botulinum Toxin Type A Treatment for Blepharospasm. Journal of the Neurological Sciences, 367, 56-62. https://doi.org/10.1016/j.jns.2016.05.033
[16]
Vermersch, P., Hobart, J., Dive-Pouletty, C., Bozzi, S., Hass, S. and Coyle, P.K. (2017) Measuring Treatment Satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose? Multiple Sclerosis Journal, 23, 604-613. https://doi.org/10.1177/1352458516657441
[17]
The Whoqol Group (1998) The World Health Organization Quality of Life Assessment (WHOQOL): Development and Psychometric Properties. Social Science & Medicine, 46, 1569-1585. https://doi.org/10.1016/S0277-9536(98)00009-4
[18]
Atkinson, M.J., Sinha, A., Hass, S.L., Colman, S.S., Kumar, R.N., Brod, M. and Rowland, C.R. (2004) Validation of a General Measure of Treatment Satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), Using a National Panel Study of Chronic Disease. Health and Quality of Life Outcomes, 2, Article No. 12. https://doi.org/10.1186/1477-7525-2-12
[19]
Foster, C.G. (1994) International Ethical Guidelines for Biomedical Research Involving Human Subjects. Journal of Medical Ethics, 20, 123-124. https://doi.org/10.1136/jme.20.2.123
[20]
World Medical Association (WMA) (2001) WMA Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects. JAMA, 310, 2191-2194. https://jamanetwork.com/journals/jama/fullarticle/1760318
[21]
Bensmail, D., Hanschmann, A. and Wissel, J. (2014) Satisfaction with Botulinum Toxin Treatment in Post-Stroke Spasticity: Results from Two Cross-Sectional Surveys (Patients and Physicians). Journal of Medical Economics, 17, 618-625. https://doi.org/10.3111/13696998.2014.925462
[22]
Reis, G.M.D., Guerra, A.C.S. and Ferreira, J.P.A. (2011) Study of Patients with Hyperhidrosis Treated with Botulinum Toxin: A 10-Year Retrospective Analysis. Brazilian Journal of Plastic Surgery, 26, 582-590.
[23]
Naumann, M., Lowe, N.J., Kumar, C.R. and Hamm, H. (2003) Botulinum Toxin Type A Is a Safe and Effective Treatment for Axillary Hyperhidrosis Over 16 Months: A Prospective Study. Archives of Dermatological, 139, 731-736. https://doi.org/10.1001/archderm.139.6.731
[24]
Meral, S.E., Tüz, H.H. and Başlarlı, Ö. (2019) Evaluation of Patient Satisfaction after Botulinum Toxin A Injection for the Management of Masticatory Myofascial Pain and Dysfunction—A Pilot Study. CRANIO®, 39, 12-16. https://doi.org/10.1080/08869634.2018.1562660
[25]
Al-Hashel, J.Y., Ahmed, S.F. and Alroughani, R. (2017) Prevalence of Primary Headache Disorders in Kuwait. Neuroepidemiology, 48, 138-146. https://doi.org/10.1159/000478892
[26]
Bruloy, E., Sinna, R., Grolleau, J.L., Bout-Roumazeilles, A., Berard, E. and Chaput, B. (2019) Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine. Plastic and Reconstructive Surgery, 143, 239-250. https://doi.org/10.1097/PRS.0000000000005111
[27]
Schaefer, S.M., Gottschalk, C.H. and Jabbari, B. (2015) Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins, 7, 2615-2628. https://doi.org/10.3390/toxins7072615
[28]
Cady, R. and Schreiber, C. (2008) Botulinum Toxin Type A as Migraine Preventive Treatment in Patients Previously Failing Oral Prophylactic Treatment Due to Compliance Issues. Headache, 48, 900-913. https://doi.org/10.1111/j.1526-4610.2007.00953.x
[29]
Luvisetto, S., Gazerani, P., Cianchetti C and Pavone F. (2015) Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders. Toxins, 7, 3818-3844. https://doi.org/10.3390/toxins7093818
[30]
Li, S., Lian, Y.J., Chen, Y., Zhang, H.-F., Ma, Y.-Q., He, C.-H., et al. (2014) Therapeutic Effect of Botulinum Toxin-A in 88 Patients with Trigeminal Neuralgia with 14-Month Follow-Up. The Journal of Headache and Pain, 15, Article No, 43. https://doi.org/10.1186/1129-2377-15-43
[31]
Durham, P.L., Cady, R. and Cady, R. (2004) Regulation of Calcitonin Gene-Related Peptide Secretion from Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy. Headache: The Journal of Head and Face Pain, 44, 35-43. https://doi.org/10.1111/j.1526-4610.2004.04007.x
[32]
Kenney, C. and Jankovic, J. (2008) Botulinum Toxin in the Treatment of Blepharospasm and Hemifacial Spasm. Journal of Neural Transmission, 115, 585-591. https://doi.org/10.1007/s00702-007-0768-7
[33]
Burns, J., Woodward, J., Truong, D., Hedges, T. and Verma, A. (2016) A Cross-Sectional Structured Survey of Patients Receiving Botulinum Toxin Type A Treatment for Blepharospasm. Journal of the Neurological Sciences, 367, 56-62. https://doi.org/10.1016/j.jns.2016.05.033
[34]
Atkinson, M.J., Sinha, A., Hass, S.L., Colman, S.S., Kumar, R.N., Brod, M. and Rowland, C.R. (2004) Validation of a General Measure of Treatment Satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), Using a National Panel Study of Chronic Disease. Health and Quality of Life Outcomes, 2, Article No. 12. https://doi.org/10.1186/1477-7525-2-12
[35]
Sidani, S., Epstein, D.R., Fox, M. and Collins, L. (2018) The Contribution of Participant, Treatment, and Outcome Factors to Treatment Satisfaction. Research in Nursing & Health, 41, 572-582. https://doi.org/10.1002/nur.21909
